EPA II Peroxidase Protection Buffer from CHEMICON

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> PRODUCTS

EPA II Peroxidase Protection Buffer from CHEMICON

Products	EPA II Peroxidase Protection Buffer from CHEMICON
Company	CHEMICON
Item	EPA II Peroxidase Protection Buffer
Price	$89.00
Description	EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods.
Info	CHEMICON CHEMICON International, Inc. 28820 Single Oak Drive Temecula, CA 92590 Customer Service: 800-437-7500 Tech Support: 800-437-7500 Fax Number: 800-437-7502 Web Site: http://www.chemicon.com

NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Rabbit Anti-Staphylococcus Enterotoxin A Polyclonal Antibody, Horseradish Peroxidase Conjugated from Abcam
2. Hydrogen Peroxide / Peroxidase Fluorometric (resorufin) Assay Kit, Fluoro H2O2 from BACHEM
3. Peroxidase, Horseradish, Conjugate-Stabilizing Solution from Calbiochem
4. EPA Peroxidase Prot.Buff from CHEMICON
5. SuperFreeze Peroxidase Conjugate Stabilizer from Pierce Biotechnology, Inc.
6. HistoMark Biotin-Streptavidin Peroxidase Kit, Rat Primary Antibody from KPL
7. HistoMark Biotin-Streptavidin Peroxidase Kit, Goat Primary Antibody from KPL
8. Rabbit Anti-Bovine Xanthine Oxidase, Buttermilk Polyclonal Antibody, Horseradish Peroxidase Conjugated from Meridian Life Science, Inc.
9. Horseradish Peroxidase (HRP) Conjugation Kit For labeling Antigens/Antibodies (Reaction Time 2 hr) from Alpha Diagnostic International Inc
10. Anti-Mouse IgGAM Polyclonal Antibody, Horseradish Peroxidase Conjugated from Invitrogen
11. Non-Protein Peroxidase Stabilizer from BioFX Laboratories, Inc.

TAG: EPA Peroxidase Protection Buffer from CHEMICON

Biology Products:

Sealed Ice Blocks, for Criterion blotter, 2 from Bio-Rad DNA Engine Tetrad 2 Thermal Cycler Chassis from Bio-Rad SVT3-2 Diverter Valve from Bio-Rad 4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI) from Pierce Biotechnology, Inc.

Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2 How to read brain activity? 2 New therapy targets for amyloid disease 2 Sex With New Partners Raises Widowers Disease Risk 57941 1 Sex With New Partners Raises Widowers Disease Risk 57941 2 URAC Open Public Comment Period for New Independent Review Organization Standards 57939 1 URAC Open Public Comment Period for New Independent Review Organization Standards 57939 2 URAC Open Public Comment Period for New Independent Review Organization Standards 57939 3 Juice Newton Performs Benefit Concert to Support Dystonia Research 57937 1 Juice Newton Performs Benefit Concert to Support Dystonia Research 57937 2

[0] Lower income women report more insurance-based discrimination during pregnancy, delivery [0] How to read brain activity?[0] New therapy targets for amyloid disease

Other Biology News:VIB and Bayer join forces for plant research 2 VIB and Bayer join forces for plant research 3 Sleep restriction results in increased consumption of energy from snacks 2 A protein sequence associated with Huntington’s disease may become life-saving vaccine component 2

VIB and Bayer join forces for plant research Sleep restriction results in increased consumption of energy from snacks A protein sequence associated with Huntington’s disease may become life-saving vaccine component

Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2 BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2 BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5 RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4

[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer [0] BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement [0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)[0] BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year